These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16266992)

  • 1. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.
    Emuss V; Garnett M; Mason C; Marais R
    Cancer Res; 2005 Nov; 65(21):9719-26. PubMed ID: 16266992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
    Ikenoue T; Hikiba Y; Kanai F; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Aragaki J; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2003 Dec; 63(23):8132-7. PubMed ID: 14678966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA; DeNicola GM; Winter SP; Tuveson DA
    Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.
    Zebisch A; Staber PB; Delavar A; Bodner C; Hiden K; Fischereder K; Janakiraman M; Linkesch W; Auner HW; Emberger W; Windpassinger C; Schimek MG; Hoefler G; Troppmair J; Sill H
    Cancer Res; 2006 Apr; 66(7):3401-8. PubMed ID: 16585161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.
    Garnett MJ; Rana S; Paterson H; Barford D; Marais R
    Mol Cell; 2005 Dec; 20(6):963-9. PubMed ID: 16364920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
    Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
    Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation and role of Raf-1/B-Raf heterodimerization.
    Rushworth LK; Hindley AD; O'Neill E; Kolch W
    Mol Cell Biol; 2006 Mar; 26(6):2262-72. PubMed ID: 16508002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
    Ikenoue T; Hikiba Y; Kanai F; Aragaki J; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2004 May; 64(10):3428-35. PubMed ID: 15150094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein.
    Brummer T; Martin P; Herzog S; Misawa Y; Daly RJ; Reth M
    Oncogene; 2006 Oct; 25(47):6262-76. PubMed ID: 16702958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
    Yuen ST; Davies H; Chan TL; Ho JW; Bignell GR; Cox C; Stephens P; Edkins S; Tsui WW; Chan AS; Futreal PA; Stratton MR; Wooster R; Leung SY
    Cancer Res; 2002 Nov; 62(22):6451-5. PubMed ID: 12438234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAF protein-serine/threonine kinases: structure and regulation.
    Roskoski R
    Biochem Biophys Res Commun; 2010 Aug; 399(3):313-7. PubMed ID: 20674547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
    Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
    Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
    J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TCR ligand avidity determines the mode of B-Raf/Raf-1/ERK activation leading to the activation of human CD4+ T cell clone.
    Tsukamoto H; Irie A; Chen YZ; Takeshita K; Kim JR; Nishimura Y
    Eur J Immunol; 2006 Jul; 36(7):1926-37. PubMed ID: 16791876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif.
    Moretti S; De Falco V; Tamburrino A; Barbi F; Tavano M; Avenia N; Santeusanio F; Santoro M; Macchiarulo A; Puxeddu E
    Biochim Biophys Acta; 2009 Nov; 1793(11):1634-45. PubMed ID: 19735675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells.
    Im E; von Lintig FC; Chen J; Zhuang S; Qui W; Chowdhury S; Worley PF; Boss GR; Pilz RB
    Oncogene; 2002 Sep; 21(41):6356-65. PubMed ID: 12214276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of Raf-1 in human pancreatic adenocarcinoma.
    Berger DH; Jardines LA; Chang H; Ruggeri B
    J Surg Res; 1997 Apr; 69(1):199-204. PubMed ID: 9202670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation of temperature-sensitive mutations in the c-raf-1 catalytic domain and expression of conditionally active and dominant-defective forms of Raf-1 in cultured mammalian cells.
    Lu KK; Bazarov AV; Yoon LS; Sedivy JM
    Cell Growth Differ; 1998 May; 9(5):367-80. PubMed ID: 9607558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raf: a strategic target for therapeutic development against cancer.
    Beeram M; Patnaik A; Rowinsky EK
    J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.